kode group

KodeRx

KodeRx was formed to take K5K, a Gen 3 KIE, from the laboratory to people with cancer: to develop it, gain market approval and supply it at a price that low- and middle-income countries can afford.

KodeRx programme: Gen 3 Kode Immunoeducer

K5K

A Kode Immunoeducer is a membrane-inserting, antibody-recruiting, complement-activating construct with adjuvant-like activity, designed to use the patient's own tumour as the antigen source for in situ vaccination.

Kode Biotech Limited owns Kode Technology and licenses it to KodeRx, Kode Agalimmune and Kode Veterinary Sciences.

K5K is a rhamnose-presenting KIE, designed to recruit pre-existing antibodies and activate complement.

Kode Veterinary Sciences is evaluating Kv9, which is identical to K5K by structure, in experimental veterinary clinical trials in New Zealand dogs, cats and horses, across multiple solid tumour types, with preliminary anti-tumour responses observed. These trials provide translational evidence for K5K. Kv9: what dogs can tell us

Shelf-stable by design: K5K can be shipped and kept for several months at room temperature, with no cold chain needed for distribution; freezer storage is recommended for the long term.

K5K is designed to be affordable, with a target treatment cost of US$5,000 per course, and accessible, with stability of at least 40°C. No cold-chain requirements.

Stage: preparing to progress to first-in-human clinical trials once funding is secured. See the steps in K5K's development path →

how Kode Immunoeducers work

KodeRx Limited

Company
NZ company 9385829
NZBN
9429053263131
Incorporated
14 November 2025
Directors
Stephen Henry
John O'Toole
Chief executive
Stephen Henry
Technology
Kode Technology licensee

K5K: designed for access

Affordability and accessibility are design requirements for K5K, set alongside the scientific ones rather than left until after approval. Four characteristics follow from that.

  • A target treatment cost under US$5,000 a course. The target covers product supply only; costs of administration, including surgery and hospital care, are not included.
  • Stability without a cold chain. K5K can be transported at room temperature and stored for several months at room temperature, reducing reliance on refrigeration and cold-chain infrastructure; long-term storage in a freezer is recommended.
  • Scalable manufacturing. K5K is a synthetic chemical entity, not a biologic, so it is made by chemical synthesis.
  • Delivery outside major specialist centres, where clinically appropriate.

These are design intentions for a programme that remains investigational. None of them is established until K5K has been through clinical development and regulatory review.

K5K: the development path

K5K is preparing to progress to first-in-human clinical trials once funding is secured.
The next stage is establishing its safety, tolerability and biological activity in people with cancer.

What stands behind it

AGI-134, a Gen 2 KIE, progressed to a Phase 1/2a human clinical study, with positive clinical findings providing important human experience with the KIE approach. Kv9, a Gen 3 KIE like K5K, is being evaluated in veterinary oncology across multiple solid tumour types, with preliminary anti-tumour responses observed. That canine work is translational evidence.

What comes next

A manufactured batch made to clinical standard, then a Phase 0 first-in-human study. Manufacture is planned in New Zealand with a GMP manufacturer licensed by Kode Biotech.

What it depends on

Funding. KodeRx works with Equitable Oncology, which coordinates the partnerships and resources needed to advance K5K, and with partners who bring capital, clinical capability or distribution reach.

K5K is investigational. It is not approved by any medicines regulator, and nothing on this page is an offer of treatment.

KodeRx partners: access and partnering

KodeRx works with Equitable Oncology, an independently governed New Zealand charity, to make K5K affordable and accessible.

Become an Equitable Oncology partner

Equitable Oncology coordinates the clinical, scientific and philanthropic partnerships that advance K5K and AGI-134.

Contact Equitable OncologyContact KodeRx

Independently governed NZ charity CC64930

The Kode Group: multiple companies, one body of science

KodeRx is one of three Kode spin-out companies developing Kode Immunoeducers.